X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (471) 471
humans (419) 419
oncology (288) 288
male (236) 236
female (228) 228
middle aged (213) 213
aged (207) 207
cancer (203) 203
adult (157) 157
chemotherapy (148) 148
treatment outcome (113) 113
surgery (110) 110
medicine & public health (103) 103
aged, 80 and over (94) 94
cholangiocarcinoma (92) 92
animals (87) 87
gastroenterology & hepatology (86) 86
pharmacology & pharmacy (84) 84
gemcitabine (83) 83
tumors (82) 82
advanced hepatocellular-carcinoma (78) 78
survival (76) 76
antineoplastic combined chemotherapy protocols - therapeutic use (75) 75
care and treatment (74) 74
prognosis (74) 74
liver (68) 68
advanced solid tumors (67) 67
phase-ii trial (64) 64
research (64) 64
clinical trials (60) 60
cell lung-cancer (59) 59
antineoplastic agents - therapeutic use (58) 58
retrospective studies (57) 57
analysis (56) 56
deoxycytidine - analogs & derivatives (55) 55
health aspects (55) 55
metastasis (52) 52
neoplasms - drug therapy (52) 52
survival rate (52) 52
article (50) 50
bile duct neoplasms - pathology (46) 46
carcinoma (46) 46
cisplatin (46) 46
radiology, nuclear medicine & medical imaging (46) 46
liver cancer (45) 45
advanced pancreatic-cancer (44) 44
intrahepatic cholangiocarcinoma (44) 44
biliary tract neoplasms - drug therapy (43) 43
cancer therapies (43) 43
neoplasm staging (43) 43
pharmacology/toxicology (43) 43
5-fluorouracil (41) 41
hepatocellular-carcinoma (40) 40
pancreatic cancer (40) 40
patients (40) 40
cholangiocarcinoma - drug therapy (39) 39
cholangiocarcinoma - pathology (39) 39
hepatocellular carcinoma (39) 39
hilar cholangiocarcinoma (39) 39
deoxycytidine - administration & dosage (38) 38
disease-free survival (38) 38
antineoplastic combined chemotherapy protocols - adverse effects (37) 37
cancer research (36) 36
capecitabine (36) 36
abridged index medicus (35) 35
bile duct neoplasms - mortality (35) 35
medical research (35) 35
bile duct neoplasms - drug therapy (34) 34
bile duct neoplasms - surgery (34) 34
radiotherapy (34) 34
adenocarcinoma (33) 33
phase-ii (33) 33
advanced gastric-cancer (32) 32
biliary tract neoplasms - pathology (32) 32
mortality (32) 32
oxaliplatin (32) 32
trial (32) 32
advanced cancer (31) 31
advanced-carcinoma (31) 31
risk factors (31) 31
sorafenib (31) 31
survival analysis (31) 31
therapy (31) 31
antineoplastic agents (30) 30
biliary tract cancer (30) 30
gastroenterology (30) 30
liver neoplasms - drug therapy (30) 30
medical prognosis (30) 30
resection (30) 30
advanced basic science (29) 29
cholangiocarcinoma - mortality (29) 29
follow-up studies (29) 29
pancreaticoduodenectomy (29) 29
antimitotic agents (28) 28
biliary-tract cancer (28) 28
combination (28) 28
gallbladder carcinoma (28) 28
hematology, oncology and palliative medicine (28) 28
maximum tolerated dose (28) 28
development and progression (27) 27
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 10/2008, Volume 113, Issue 8, pp. 2119 - 2128
Journal Article
Strahlentherapie und Onkologie, ISSN 0179-7158, 9/2012, Volume 188, Issue 9, pp. 795 - 801
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2013, Volume 133, Issue 9, pp. 2065 - 2076
Journal Article
Gastroenterology, ISSN 0016-5085, 03/2018, Volume 154, Issue 4, pp. 1066 - 1079.e5
Cholangiocarcinomas (CCA) are resistant to chemotherapy, so new therapeutic agents are needed. We performed a screen to identify small-molecule compounds that... 
Organoid | Bile Duct Cancer | DNAJB5 | AUY922 | BILIARY-TRACT CANCER | INTRAHEPATIC CHOLANGIOCARCINOMA | ADVANCED SOLID TUMORS | PANCREATIC-CANCER | ACQUIRED-RESISTANCE | I DOSE-ESCALATION | TYROSINE KINASE INHIBITORS | HSP90 INHIBITORS | PROSTATE-CANCER | GASTROENTEROLOGY & HEPATOLOGY | MICRORNA EXPRESSION | Humans | Gene Expression Regulation, Neoplastic | MicroRNAs - metabolism | Cholangiocarcinoma - metabolism | Dose-Response Relationship, Drug | Transfection | Organoids | Time Factors | Antineoplastic Agents - pharmacology | HSP90 Heat-Shock Proteins - genetics | Bile Duct Neoplasms - genetics | Tumor Cells, Cultured | Nuclear Proteins - genetics | Bile Duct Neoplasms - drug therapy | Cell Survival - drug effects | HSP40 Heat-Shock Proteins - metabolism | Bile Duct Neoplasms - metabolism | HSP40 Heat-Shock Proteins - genetics | Isocitrate Dehydrogenase - genetics | Transcription Factors - genetics | Mice, SCID | Xenograft Model Antitumor Assays | Cholangiocarcinoma - pathology | Drug Resistance, Neoplasm - genetics | Animals | Cholangiocarcinoma - drug therapy | Signal Transduction - drug effects | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Cell Line, Tumor | Cholangiocarcinoma - genetics | HSP90 Heat-Shock Proteins - metabolism | Mice, Inbred NOD | MicroRNAs - genetics | Bile Duct Neoplasms - pathology | Mutation | Index Medicus | Abridged Index Medicus | FFPE, formalin-fixed paraffin-embedded | FGFR, fibroblast growth factor receptor | WT, wild type | PDO, patient-derived organoid | GI, growth inhibition | miRNA, microRNA | HTS, high-throughput screen | DMSO, dimethyl sulfoxide | HSP, heat shock protein | iCCA, intrahepatic cholantiocarcinoma | CCA, cholangiocarcinoma
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2015, Volume 33, Issue 24, pp. 2617 - 2622
Journal Article